# A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

> **NCT06192108** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 962 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Orforglipron
- **DRUG:** Dapagliflozin

## Key facts

- **NCT ID:** NCT06192108
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-10
- **Primary completion:** 2025-09-26
- **Final completion:** 2025-09-26
- **Target enrollment:** 962 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192108, "A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06192108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*